智飞生物CA111注射液获临床试验批准

Core Viewpoint - Zhifei Biological announced that its subsidiary, Chongqing Chen'an Biopharmaceutical Co., Ltd., received approval from the National Medical Products Administration for clinical trials of CA111 injection in overweight or obese adults [1] Group 1 - The CA111 injection is a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor [1] - Compared to single-target similar drugs, the dual agonist can effectively reduce the side effects of administration due to synergistic and complementary effects [1]